Role of the endocannabinoid system in depression: From
preclinical to clinical evidence

C 2015

Role of the endocannabinoid system in depression: From preclinical to clinical evidence

MICALE, Vincenzo; Katarína TABIOVÁ; Jana KUČEROVÁ a F. DRAGO

Základní údaje

Originální název

Role of the endocannabinoid system in depression: From preclinical to clinical evidence

Autoři

MICALE, Vincenzo; Katarína TABIOVÁ; Jana KUČEROVÁ a F. DRAGO

Vydání

New York, Cannabinoid Modulation of Emotion, Memory, and Motivation, od s. 97-129, 33 s. XIV, 2015

Nakladatel

Springer New York

Další údaje

Jazyk

angličtina

Typ výsledku

Kapitola resp. kapitoly v odborné knize

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Forma vydání

tištěná verze "print"

Odkazy

URL

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/15:00084726

Organizační jednotka

Středoevropský technologický institut

ISBN

978-1-4939-2294-9

DOI

https://doi.org/10.1007/978-1-4939-2294-9_5

EID Scopus

2-s2.0-84944597847

Klíčová slova anglicky

Animal models; Antidepressants; Cannabidiol; CB1 and CB2 receptors; Depression; Endocannabinoid system; TRPV1 channels; delta9-THC

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 4. 2016 11:21, Olga Křížová

Anotace

V originále

The endogenous cannabinoid system (ECS) works as pro-homeostatic and pleiotropic signaling system activated in a time- and tissue-specific way during physiological conditions, which include cognitive, emotional and motivational processes. It is composed of two G protein-coupled receptors (the cannabinoid receptors types 1 and 2 [CB1 and CB2] for marijuana’s psychoactive ingredient delta 9-tetrahydrocannabinol [delta 9-THC]), their endogenous small lipid ligands (anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and the proteins for endocannabinoid biosynthesis and deactivation. Data from preclinical and clinical studies have reported that a hypofunction of the endocannabinoid signaling could induce a depressive-like phenotype; consequently, enhancement of endocannabinoid signaling could be a novel therapeutic avenue for the treatment of depression. To this aim there have been proposed cannabinoid receptor agonists or synthetic molecules that inhibit endocannabinoid degradation. The latter ones do not induce the psychotropic side effects by direct CB1 receptor activation, but rather elicit antidepressant-like effects by enhancing the monoaminergic neurotransmission, promoting hippocampal neurogenesis and normalizing the hyperactivity of hypothalamic-pituitary-adrenal axis, similarly as the standard antidepressants. The dysfunction of elements belonging to the ECS and the possible therapeutic use of endocannabinoid deactivation inhibitors and phytocannabinoids in depression is discussed in this chapter. © Springer Science+Business Media New York 2015.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

Citovat

MICALE, Vincenzo; Katarína TABIOVÁ; Jana KUČEROVÁ a F. DRAGO. Role of the endocannabinoid system in depression: From preclinical to clinical evidence. In Campolongo Patrizia, Fattore Liana. Cannabinoid Modulation of Emotion, Memory, and Motivation. New York: Springer New York, 2015, s. 97-129. XIV. ISBN 978-1-4939-2294-9. Dostupné z: https://doi.org/10.1007/978-1-4939-2294-9_5.

@inbook{1317676,
   author = {Micale, Vincenzo and Tabiová, Katarína and Kučerová, Jana and Drago, F.},
   address = {New York},
   booktitle = {Cannabinoid Modulation of Emotion, Memory, and Motivation},
   doi = {https://doi.org/10.1007/978-1-4939-2294-9_5},
   editor = {Campolongo Patrizia, Fattore Liana},
   keywords = {Animal models; Antidepressants; Cannabidiol; CB1 and CB2 receptors; Depression; Endocannabinoid system; TRPV1 channels; delta9-THC},
   howpublished = {tištěná verze "print"},
   language = {eng},
   location = {New York},
   isbn = {978-1-4939-2294-9},
   pages = {97-129},
   publisher = {Springer New York},
   title = {Role of the endocannabinoid system in depression: From preclinical to clinical evidence},
   url = {http://www.springer.com/us/book/9781493922932},
   year = {2015}
}

TY  - CHAP
ID  - 1317676
AU  - Micale, Vincenzo - Tabiová, Katarína - Kučerová, Jana - Drago, F.
PY  - 2015
TI  - Role of the endocannabinoid system in depression: From preclinical to clinical evidence
VL  - XIV
PB  - Springer New York
CY  - New York
SN  - 9781493922949
KW  - Animal models
KW  - Antidepressants
KW  - Cannabidiol
KW  - CB1 and CB2 receptors
KW  - Depression
KW  - Endocannabinoid system
KW  - TRPV1 channels
KW  - delta9-THC
UR  - http://www.springer.com/us/book/9781493922932
L2  - http://www.springer.com/us/book/9781493922932
N2  - The endogenous cannabinoid system (ECS) works as pro-homeostatic and pleiotropic signaling system activated in a time- and tissue-specific way during physiological conditions, which include cognitive, emotional and motivational processes. It is composed of two G protein-coupled receptors (the cannabinoid receptors types 1 and 2 [CB1 and CB2] for marijuana’s psychoactive ingredient delta 9-tetrahydrocannabinol [delta 9-THC]), their endogenous small lipid ligands (anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and the proteins for endocannabinoid biosynthesis and deactivation. Data from preclinical and clinical studies have reported that a hypofunction of the endocannabinoid signaling could induce a depressive-like phenotype; consequently, enhancement of endocannabinoid signaling could be a novel therapeutic avenue for the treatment of depression. To this aim there have been proposed cannabinoid receptor agonists or synthetic molecules that inhibit endocannabinoid degradation. The latter ones do not induce the psychotropic side effects by direct CB1 receptor activation, but rather elicit antidepressant-like effects by enhancing the monoaminergic neurotransmission, promoting hippocampal neurogenesis and normalizing the hyperactivity of hypothalamic-pituitary-adrenal axis, similarly as the standard antidepressants. The dysfunction of elements belonging to the ECS and the possible therapeutic use of endocannabinoid deactivation inhibitors and phytocannabinoids in depression is discussed in this chapter. © Springer Science+Business Media New York 2015.
ER  -

MICALE, Vincenzo; Katarína TABIOVÁ; Jana KUČEROVÁ a F. DRAGO. Role of the endocannabinoid system in depression: From preclinical to clinical evidence. In Campolongo Patrizia, Fattore Liana. \textit{Cannabinoid Modulation of Emotion, Memory, and Motivation}. New York: Springer New York, 2015, s.~97-129. XIV. ISBN~978-1-4939-2294-9. Dostupné z: https://doi.org/10.1007/978-1-4939-2294-9\_{}5.

Přehled o publikaci